Summary Xenografts originated from human tumours offer the most appropriate research material for in vivo experimental research. However, primary human breast carcinomas are difficult to grow when transplanted in athymic mice: tumour take is less than 15%. Recently, we have achieved 60% tumour take by injecting tumour cell suspensions mixed with Matrigel. Human breast xenografts originated from primary breast carcinoma also frequently show the potential to metastasize spontaneously. In the present study, we generated a human breast carcinoma xenograft line (UISO-BCA-NMT-18) that shows 100% tumorigenicity and 80-100% lung metastasis when transplanted s.c. in athymic mice. We have studied in detail the characteristics of the xenograft and the patient's tumour from which the xenograft line originated. Both the xenograft and the patient's tumour showed intense staining for mutant p53 nuclear protein, and high expression of U-PA, PAI and u-PAR. In vivo growth of the xenograft is stimulated by exogenous supplementation of oestrogen. This xenograft is continuously growing in mice and has shown 80-100% metastasis for the last three successive in vivo passages. This well-characterized, oestrogenresponsive, metastatic breast carcinoma xenograft line will provide excellent research material for metastasis-related research.
Metastasis of primary tumour to the visceral organs is a major cause of cancer-associated mortality. Despite considerable progress in the last decade in the areas of early detection and surgical and chemotherapeutic management of clinically less advanced cancers, treatment of metastatic disease is still a major puzzle for oncologists. Research on metastatic disease has severely suffered from lack of suitable experimental models. Human tumour xenografts established from well-characterized clinical material provide an important research tool for multidisciplinary research. In most cases, xenografts originated in vivo in experimental animals preserve many of the original phenotypic, biological and genotypic characteristics from which they originate (Giovanella et al, 1989; Mehta et al, 1995a) . However, human breast carcinomas are difficult to grow in vitro in culture (Nordquist et al, 1975; Engel and Young, 1978; Langlois et al, 1979; Whitehead et al, 1983; Chu et al, 1985; Mehta et al, 1992;  1995b ; Watanabe et al, 1992) or in vivo in experimental animals (Sabestany et al, 1979; Shafie and Liotta, 1980; Rae-Venter and Reid, 1980; Giovanella et al, 1985; Price and Zhang, 1990; Hurst J, et al, 1993; Mehta et al, 1993) , and they rarely metastasize when transplanted subcutaneously (Shafie and Liotta, 1980; Price et al, 1990; Brunner et al, 1992; Mehta et al, 1993) .
Recently, we obtained significant success in establishing xenografts from primary breast carcinomas, and many of these xenografts showed potential for spontaneous metastasis in athymic mice when transplanted s.c. (Mehta et al, 1993) . Initially, we used Matrigel to develop xenografts from primary breast carcinomas (Mehta et al, 1993; 1995a) . Matrigel is a mixture of components usually found in the extracellular matrix. The major components of Matrigel are laminin, collagen IV, heparan sulphate and entactin. Matrigel not only increased the take rate of human breast carcinoma in athymic mice, but also promoted spontaneous metastasis in approximately 40% of tumours (Mehta et al, 1993) . In the present study, we further explored the metastatic potential of a xenograft by serial repetitive in vivo/in vitro propagation of a human breast xenograft originated in mice. We have established a human breast carcinoma xenograft line that is 80-100% metastatic when transplanted s.c. in athymic mice.
MATERIAL AND METHODS Procurement of human breast carcinoma
Primary human breast carcinoma was obtained from a 41-year-old woman with confirmed diagnosis of primary human breast carcinoma undergoing lumpectomy procedure. After surgical excision, tumour tissue was immediately transported to the laboratory on wet ice. Detailed information regarding histopathological details of the tumour and the patient's disease status was obtained from our tumour registry.
Enzymatic digestion of tumour
Tumour tissue was divided into small pieces, one of which was fixed in 10% formalin and processed for histological and immunohistochemical analysis of various biomarkers. The remaining tissue (approximately 0.2-0.3 g) was minced into small pieces and mixed (1:10 volume) with a cocktail of enzymes composed of 0.002% deoxyribose nuclease type 1 (Sigma, St Louis, MO, USA), 0.1 % collagenase (United States Biochemical Corporation, Cleveland, OH, USA) and 0.01% hyaluronidase type V (Sigma, St Louis, MO, USA) The tumour suspension was injected into the mammary fat pad of 3-to 4-week-old female athymic (Balb/c) mice (Frederick Cancer Research Facility, Frederick, MD, USA). Animals were observed for development of a palpable tumour; if a tumour developed the tumour size (cm) was measured in three different planes as height (h), width (w) and depth (d), using vernier calipers.
Tumour volume (cm3) was calculated using the formula h x w x d x n/6 = cm3. For this study, the tumour doubling time was calculated as the number of days required during the exponential growth phase for the tumour to grow from x volume to 2x volume. The tumour latency period is the time (days) required for the tumour to show apparent sustained increase in volume from the initial volume of injected suspension or xenograft.
Animals were killed if they became moribund, had necrosis in the tumour, or if the tumour volume reached > 2.5 cm' in volume.
All animals at termination were examined for metastatic lesions in the visceral organs. Suspected lesions were processed for histopathological examinations. The tumour that developed at the inoculation site was divided into small pieces and processed for histological studies, further in vivo propagation and studies of various biochemical and immunohistochemical biomarkers.
Serial in vivo processing of human tumour xenograft in athymic mice
The xenograft developed at the original inoculation site was divided into small pieces and then trocared s.c. into athymic mice. Matrigel was not used for serial transplantation of xenografts. Tumour that developed during each serial passage was processed 
Immunohistochemical analyses of various proteins
Immunohistochemical analyses of various protein biomarkers in the original breast tumour and in the xenograft developed in mice were performed by the indirect immunoperoxidase method, with a labelled streptavidin-biotin complex kit (Dako Corporation, Carpinteria, CA, USA). In brief, 4-to 5-jm-thick sections of formalin-fixed paraffin-embedded tissues were mounted on frosted microslides, and sections were deparaffinized in xylene and rehydrated by processing through a graded series of alcohol (100-0%). The tissue sections were rinsed in phosphate-buffered saline (PBS) and then microwaved three times for 5 min in citrate buffer (c-neu, Cathepsin) or in 6 M urea (p53) at 80% power. For U-PA, PAI-I and UPAR studies, rehydrated tissue sections were incubated for 30 min in 0.1% trypsin at 370C. The sections were extensively washed with PBS.
To block non-specific binding, sections were incubated at room temperature in 5% non-fat dry milk for 10 min. Tissue sections were rinsed in PBS and then incubated at 40C overnight in the moisture chambers with appropriate diluted specific primary antibody. Tissue that had been incubated with mouse IgG (5 jig ml-i) served as an experimental control. At the end of the incubation, sections were extensively rinsed in PBS, then incubated with biotinylated antimouse/anti-rabbit link antibody for 10 min and with peroxidaseconjugated streptavidin for 10 min. Staining was visualized using 3-amino 9-ethyl carbazole (AEC) or 3,3'-diaminobenzidine as chromogen (Biogenex, San Ramon, CA, USA). Tissues were 
RESULTS
Characteristics of human breast carcinoma Histopathologically, the original patient's tumour was classified as infiltrating ductal carcinoma of the breast ( Figure IA) . At the time of surgery, no evidence of disease having spread to the axillary lymph nodes was reported. The tumour was immunohistochemically positive for ER and PR and strongly positive for p53 and intensely stained for nm23. The tumour showed weak to moderate cytoplasmic staining for cathepsin D, strong cell membraneassociated staining for PAI, U-PAR and U-PA. The tumour showed strong immunoreactivity to Her-2/neu antibody (mouse monoclonal antibody against a specific peptide sequence from the The tumour latency period in this passage was 20 days. The tumour doubling time at passage 1 was between 5 and 8 days. The tumour was hard and localized at the inoculation site. During successive serial passaging, 100% tumour formation was observed in animals. The xenografts at each in vivo passaging were confirmed to have human origin by LDH isoenzyme assay (data not shown).
Characterization of human breast xenograft
Light microscopy of the xenograft at passage 1 showed small clusters of human breast carcinoma cells embedded in host stromal tissue. At passage 2, cell clusters grew more compact and had minimal presence of host stromal tissue elements. The xenograft from which 100% lung metastasis was first observed (passage 7) showed histopathology similar to that of the original patient's tumour. The clusters of tumour cells were infiltrated in host stromal tissue, and evidence was frequently observed of necrotic tissue scattered throughout the tumour tissue. At this time, many tumour cells were seen at the different phases of cell division (Figure 2A-C) .
Immunohistochemical analyses of various biomarkers were performed on the xenograft at in vivo passages 2 and 3 (before generating the metastatic line). Immunohistochemically, detectable specific staining was observed against Her-2/neu, p53 ( Figure  3A-B) , and nm23 (data not shown). The presence of Her-2/neu protein was further confirmed by Western blot analysis of xenograft extract ( Figure 4A ). Because nm23 antibody used in the present study cross-reacts with two different proteins (nm23-HI and nm23-H2), we performed Western blot analysis on xenograft lysate. On the SDS gel using denaturing condition in the cytosolic extract, we observed two specific proteins immunoreactive to nm23 antibody, approximately molecular weight 17 000 and 18 000 representing both nm23-H1 and nm23-H2 proteins ( Figure 4B ). (1998) We failed to observe specific immunoreactivity to antibodies against ER, PR or cathepsin D in the xenograft. We observed mild to moderate membrane-associated staining in the xenograft for U-PA, UPAI and UPAR ( Figure 5A -C).
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Development of metastatic human breast xenograft line
The growth pattern of the xenograft during passage 1-7 shows that, at early passages, growth was initially slow; however, after passage 5, growth was enhanced. Initially, during passages 1-4, the tumour showed longer tumour latency time and failed to achieve true exponential growth. After passage 5, the tumour began to show increased growth between 13-20 days; tumour doubling time was between 8 and 9 days ( Figure 6 ). Human breast xenograft serially transplanted for six passages in athymic mice showed no evident metastasis to visceral sites at any passages. However, in the seventh passage, one out of three animals had lung metastasis. At this time, the lung lesion was transplanted s.c. in one animal to expand the tumour material, and the tumour that developed at the injection site was passaged in two animals. The xenografts developed in these animals were minced, and a small portion was cultured in vitro and the remaining tissues were retransplanted in mice and serially passaged.
The cells growing in culture from xenograft were transplanted s.c. in two animals. At this time, one out of two animals showed metastatic tumour in the lung. The xenograft developed at the site of inoculation from the later animal was transplanted into five animals. All five animals developed tumours and attained experimental growth phase within 20-25 days; the tumour doubling time in these animals was between 10 and 12 days. All five animals showed metastasis in the lung (Met-1). We excised the xenografts growing at the inoculation site from this last group of animals and transplanted them into 15 animals. All 15 animals had tumours growing at the inoculation site (Met-2) within 17-20 days, and 13 out of 15 animals had lung metastasis. In the next transplantation (Met-3) into the animals, lung metastasis was found in 13 out of 14 animals. Figure 7 shows in vivo growth of xenografts with >80% metastatic potential in vivo.
The xenografts serially passaged (to passage 12) in vivo without in vitro propagation were 100% tumorigenic and showed occasional incidence (10-20%) of lung metastasis. Detailed analysis of growth pattern showed that, in general, xenografts developed in these animals had a relatively longer tumour doubling time (ranging between 15 and 18 days, mean tumour doubling time = 16.8 + 0.9 days) compared with those xenografts with higher metastatic ability. Figure 8 shows the growth of xenografts during serial in vivo transplantation. Figure 9 shows representative metastatic lesions developed in mice. The number and volume or size of metastatic tumours in the lungs varied widely from animal to animal and in vivo passage to passage. Occasionally, we observed multiple metastatic tumours in both lungs; however, most animals had 1-2 lesions per lung. Histologically, lesions formed in the lungs were identical to the xenograft developed at the subcutaneous site.
British Journal of Cancer (1998) 77(4), [595] [596] [597] [598] [599] [600] [601] [602] [603] [604] . Figure 10 , growth of xenografts transplanted without Matrigel into athymic mice bearing oestradiol pellets (0.1 mg) was significantly (P < 0.05) higher than those transplanted into control animals with placebo pellets. Interestingly, at the termination of the experiment, five out of five mice treated with placebo pellets showed metastatic lesions in the lungs; however, zero out of five animals treated with oestradiol showed lung metastasis.
DISCUSSION
Breast cancer is the most common cancer among women and the second leading cause of cancer-related death in women. Although significant progress has been made in the last decade for early detection of tumours and treatment of clinically less advanced carcinoma, management of advanced breast cancer has still not improved. The process of metastasis is complex: it involves cascades of various biochemical and molecular steps (Liotta et al, 1983; Nicolson, 1988) . Factors associated with both the host tissue and the malignant cells play crucial roles in the invasion and metastasis of tumour cells (Boghaert et al, 1992; Lester and McCarthy, 1992) . Even though various investigators are engaged in understanding the actual molecular and biological steps in the process of metastasis, the exact mechanism of the process is still not fully understood. In addition, research on evaluating new antimetastatic drugs for breast cancer is severely hampered because of the unavailability of suitable experimental models for breast cancer metastasis.
For experimental research on metastatic disease, a reliable experimental tool is necessary. At present, numerous breast carcinoma cell lines established from primary solid human breast carcinoma or from the metastatic pleural fluids are available for various research (Nordquist et al, 1975; Engel and Young, 1978; Langlois et al, 1979; Whitehead et al, 1983; Chu et al, 1985; Mehta et al, 1992; 1995b; Watanabe et al, 1992; Slooten et al, 1995) ; however, only a limited number of these cell lines are tumorigenic in mice, and only two to three of these cell lines show distant metastasis when transplanted s.c. into athymic mice (Shafie and Liotta, 1980; Price et al, 1990; Brunner et al, 1992; Mehta et al, 1993) . In addition the incidence of metastasis in these cell lines varies in different laboratories (Shafie and Liotta, 1980) . Thus, establishment of a well-characterized human breast carcinoma xenograft line with highly tumorigenic and metastatic potential in experimental animals is of great value in metastatic research.
In general, human breast carcinomas fail to grow when transplanted into athymic mice. The tumour take of human breast tumours is generally about 6-15% (Shafie and Liotta, 1980; Mehta et al, 1993) . In our laboratory, tumour take is generally >60% when enzymically digested tumours are injected into mice mixed with Matrigel (Mehta et al, 1993; 1995a) . Matrigel not only increased tumour take but also enhanced tumour growth and facilitated spontaneous distant metastasis (Mehta et al, 1993) . In the present study, we have established a human breast carcinoma xenograft line from a primary human breast carcinoma using Matrigel as described previously (Mehta et al, 1993; Mehta et al, 1995a; ) .
To establish a xenograft in athymic mice, the original patient's tumour was digested with a cocktail of enzymes, and the resulting cell suspension was pelleted and mixed with Matrigel then injected into athymic mice. Initially, during the first in vivo passage, the tumour grew as a small nodule at the site of the original tumour inoculation. However, in subsequent serial passaging, 100% of animals showed tumour growth at the site of the original xenograft transplantation. During serial passaging, inconsistent but occasional incidence of lung metastasis was observed in animals, suggesting metastatic potential of the xenograft. We expanded the metastatic tumour cells in the xenograft by in vivo passaging of lung lesions. We further cultured the metastatic tumour in vitro and then inoculated the culture in vivo. Further continuous in vivo passaging of breast xenograft developed from a metastatic lesion generated a xenograft line that is 80-100% tumorigenic in athymic mice for the last three successive in vivo passages. The xenografts continuously passaged in vivo without in vitro exposure have maintained low metastatic potential. From our results it is evident that during in vitro culturing of a xenograft originating from a metastatic lesion, the selection of highly aggressive and metastatic cells occurs.
It appears that, during serial in vivo passaging, gradual changes in xenograft histopathology occurred. Initially, at passage 1, the xenograft showed small clusters of cells embedded in host stromal tissues. In passage 2 and thereafter, most of the tumour was packed with malignant breast cells with minimal presence of the host stromal tissue. In later passages, the xenograft histology appeared to be similar to that of human breast tumour-that is tumour cells were infiltrated in the host stroma as clusters of cells simulating infiltrating ductal carcinoma histopathology.
The xenograft UISO-NMT-BCA-18 preserved many phenotypic characteristics of the patient's tumour from which it originated. The original patient's tumour was positive for mutant type p53, a tumour-suppressor nuclear phosphoprotein. The patient's tumour also had high expression of U-PA, PAI and UPAR. All these markers are associated with highly aggressive breast cancer (Slamon et al, 1987; Berger et al, 1988; Clark and McGuire 1991; Allred et al, 1992; Caleffi et al, 1994; Gasparini et al, 1994; McDonald et al, 1995; Hamby et al, 1996) . We observed intense immunoreactivity against antibodies to human Her-2/neu in the patient's tumour. A similar staining pattern was also evident in the xenograft. We further confirmed the presence of overexpressed cerbB2 in xenografts using Western blot analysis. More recently, two additional genes called nm23-1 and nm23-2 are thought to influence the metastatic potential of malignant tumours (McDonald et al, 1995; Hamby et al, 1996) . Experimental evidence suggests that altered expression of nm23-1 or nm23-2 protein is associated with increased metastatic potential (McDonald et al, 1995; Hamby et al, 1996) . The patient's original tumour showed enhanced expression of nm23 protein immunohistochemically. The antibody used in our assay detects both nm23-1 and nm23-2 proteins. Thus, enhanced nm23 expression observed in the patient's tumour is probably the result of altered levels of nm23-2 protein levels compared with nm23-1; using Western blot analysis, we detected high levels of nm23-1 protein in the xenograft at early passages. Similarly, U-PA, PAI and UPAR have been shown to have prognostic significance (Janicke et al, 1993; Bouchet et al, 1994; Duffy et al, 1994; Foekens et al, 1994; Foekens et al, 1995) . Thus, this xenograft line is ideal for evaluating new chemotherapeutic agents that will effectively prevent metastasis of highly aggressive tumours.
The patient's tumour had positive immunoreactivity for ER, PR and cathepsin D. In the xenograft at passages 2 and 3, we failed to New metastatic breast xenograft line 603 detect ER by immunohistochemical assay. However, increased growth response to exogenously supplemented oestrogen observed in later passages in the line with metastatic ability compared with the placebo control group suggests that these tumour lines have maintained functional ER status. Failure to detect ER in xenograft tumours could be due to down-regulation of this protein by endogenous ligands (in mice) of c-erbB2. Two different ligands, gp3O and p75, have been shown to down-regulate in a dose-dependent manner the expression of ER in ER positive BT-474 and MCF-7 breast carcinoma cell lines in oestrogen-depleted medium (Grunt et al, 1995) . On the contrary, low levels of oestrogen (0.1-1 nM) treatment to oestrogen-responsive MCF cells have been reported to cause a rapid but sustained drop in Her-2/neu mRNA (Read et al, 1990) , suggesting that oestrogen has a differential effect on the markers associated with tumour aggressiveness and cell proliferation. Our results on in vivo growth and metastatic behaviour of UISO-NMT-BCA-8 in mice in the presence/absence of oestrogen are in agreement with those obtained in vitro in human breast cancer cells by Read and associates (1990) . In athymic mice, UISO-BCA-NMT-18 showed increased growth by oestradiol but showed inhibition of metastatic potential compared with untreated controls. In this tumour line, down-regulation of Her-2/neu expression by oestradiol may inhibit tumour metastasis. Further detailed studies are currently in progress to understand the mechanism of oestradiol action on various molecular markers associated with breast carcinoma cell proliferation and metastasis.
In summary, the human breast xenograft reported in the present study is of great value for human breast cancer research. Currently, for metastatic breast cancer research MDA-MB-231 and MDA-MB-435 are widely used (Brunner et al, 1992; . Both these cell lines were originated from metastatic pleural effusion, are highly tumorigenic, and have high metastatic potential. In addition, both these cell lines have been reported to be ER-negative. To the best of our knowledge, no reliable, highly metastatic ER-positive cell line or xenograft line is available for research. In general, the UISO-NMT-BCA-18 xenograft line differs from the existing metastatic lines as it originated from primary human breast carcinoma and is responsive to oestrogen. Thus, the addition of a wellcharacterized ER-positive tumour line to an existing panel of metastatic human breast carcinoma cell lines will provide a valuable tool with which to study the role of various oestrogenregulated genes in metastasis of human breast cancer.
